July 08, 2020 11:16 pm | Updated 11:16 pm IST - bengaluru
Drugmaker Cipla Ltd. has priced its generic version of Remdesivir, Cipremi, at ₹4,000 rupees per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally.
Cipla had earlier said pricing would not exceed ₹5,000. Sovereign Pharma, which is manufacturing and packaging the drug, which will be available only through government and hospitals, said it had dispatched the first batch.
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.
